Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA9181
Study Title: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR ABL positive Acute Lymphoblastic Leukemia (ALL) in Adult
CTO #: 103770
NCT Number: NCT04530565
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lymphoid Leukemia
Study Objectives: This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.